TUSTIN, CA, and BELLEVUE, WA--(Marketwire - March 09, 2011) - Avid Bioservices, Inc., a leading provider of integrated commercial and clinical manufacturing services and a subsidiary of Peregrine Pharmaceuticals, Inc., announced that it will present a poster with data from successful comparability studies of the large-scale manufacturing of a clinical-stage chimeric monoclonal antibody at the IBC Biopharmaceutical Development and Production Week Conference at the Hyatt Regency Bellevue, Washington, March 14-18, 2011. These studies, which were submitted to the U.S. Food and Drug Administration (FDA), compared and demonstrated equivalency of a chimeric monoclonal antibody manufactured in 1,000 liter stainless steel and single-use bioreactor (SUB) systems.
Avid will also host an exhibit at the conference, booth #208, March 14-18, 2011 at the Hyatt Regency Bellevue, Washington. For additional information on IBC's Biopharmaceutical Development & Production Week, please visit www.IBCLifeSciences.com/BDPWeek.
About Avid Bioservices
Avid Bioservices provides a comprehensive range of high quality cGMP manufacturing services for the biotechnology and biopharmaceutical industries to support manufacturing of cGMP commercial and clinical products. With over 10 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cell banking, stability testing, clinical and commercial product manufacturing and purification, bulk packaging, final product filling and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line optimization, analytical methods development and product characterization. For more information about Avid, please visit www.avidbio.com.
About Peregrine Pharmaceuticals
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) is a biopharmaceutical company with a portfolio of innovative monoclonal antibodies in clinical trials for the treatment of cancer and serious viral infections. The company is pursuing three separate clinical programs in cancer and hepatitis C virus infection with its lead product candidates bavituximab and Cotara®. Peregrine also has in-house cGMP manufacturing capabilities through its wholly owned subsidiary Avid Bioservices, Inc., which provides development and biomanufacturing services for both Peregrine and outside customers. Additional information about Peregrine can be found at www.peregrineinc.com.